COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Comparison of Brimonidine Purite, Dorzolamide, and Brinzolamide as Adjunctive Therapy to Prostaglandin Analogs

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00675207
Recruitment Status : Completed
First Posted : May 8, 2008
Last Update Posted : May 8, 2008
Research to Prevent Blindness
Information provided by:
Northwestern Ophthalmic Institute S.C.

Brief Summary:
The purpose of this study is to compare the efficacy of brimonidine Purite, dorzolamide, and brinzolamide in reducing intraocular pressure when added to prostaglandin analog therapy (bimatoprost, latanoprost, or travoprost) in patients with glaucoma or ocular hypertension.

Condition or disease Intervention/treatment Phase
Primary Open Angle Glaucoma Ocular Hypertension Drug: Brimonidine purite 0.15% Drug: Dorzolamide 2% Drug: Brinzolamide 1% Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Investigator)
Primary Purpose: Treatment
Official Title: Comparison of Brimonidine 0.15% Purite, Dorzolamide 2%, and Brinzolamide 1% as Adjunctive Therapy to Prostaglandin Analogs
Study Start Date : January 2006
Actual Primary Completion Date : July 2007
Actual Study Completion Date : July 2007

Arm Intervention/treatment
Active Comparator: 1
Brimonidine purite 0.15%
Drug: Brimonidine purite 0.15%
A single drop of brimonidine purite 0.15% ophthalmic solution administered topically in the eye 3 times daily.
Other Name: Alphagan P 0.15%

Active Comparator: 2
Dorzolamide 2%
Drug: Dorzolamide 2%
A single drop of dorzolamide 2% ophthalmic solution administered topically in the eye 3 times daily.
Other Name: Trusopt

Active Comparator: 3
Brinzolamide 1%
Drug: Brinzolamide 1%
A single drop of brinzolamide 1% ophthalmic solution administered topically in the eye 3 times daily.
Other Name: Azopt

Primary Outcome Measures :
  1. Intraocular pressure [ Time Frame: Measurements at peak and trough effect (10 am and 4 pm) at baseline, month 1, and month 4 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   41 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of primary open-angle glaucoma or ocular hypertension.
  • Must be over 40 years of age.
  • Intraocular pressure must be 18 mm Hg or higher after 6 weeks of treatment (run-in) with a prostaglandin analog (bimatoprost, latanoprost, or travoprost).

Exclusion Criteria:

  • History of angle closure or narrow angle.
  • Previous intraocular surgery.
  • Laser trabeculoplasty within 3 months prior to screening.
  • History of uveitis or intraocular inflammation.
  • Use of medications other than the study medications that are known to affect IOP (e.g., beta-blockers, steroids, or angiotensin II blockers) within 3 months of study entry or during the study.
  • Intolerance of or hypersensitivity to prostaglandin analogs, sulfonamides, alpha-agonists, or the preservative benzalkonium chloride.
  • Women of childbearing age who are pregnant or not using contraception.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00675207

Layout table for location information
United States, Illinois
Northwestern Ophthalmic Institute S.C.
Glenview, Illinois, United States, 60026
Sponsors and Collaborators
Northwestern Ophthalmic Institute S.C.
Research to Prevent Blindness
Layout table for investigator information
Principal Investigator: Thomas E. Bournias, MD Northwestern Ophthalmic Institute S.C.
Layout table for additonal information
Responsible Party: Thomas E. Bournias, Northwestern Ophthalmic Institute S.C. Identifier: NCT00675207    
Other Study ID Numbers: NWOIADJ 2006
First Posted: May 8, 2008    Key Record Dates
Last Update Posted: May 8, 2008
Last Verified: May 2008
Keywords provided by Northwestern Ophthalmic Institute S.C.:
ocular hypertension
adjunctive treatment
prostaglandin analog
alpha agonist
carbonic anhydrase inhibitor
intraocular pressure
Additional relevant MeSH terms:
Layout table for MeSH terms
Glaucoma, Open-Angle
Ocular Hypertension
Vascular Diseases
Cardiovascular Diseases
Eye Diseases
Brimonidine Tartrate
Antihypertensive Agents
Adrenergic alpha-2 Receptor Agonists
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Carbonic Anhydrase Inhibitors
Enzyme Inhibitors